| Adjuvant taxanes: more to the story. | |
| | |
MedLine Citation:
|
PMID: 20805064 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Breast cancer is a common public health problem, and the most important prognostic factors in survival or recurrence after potentially curative surgery include the number of involved axillary lymph nodes and the biology of the disease. Systemic chemotherapy remains a critical component in the eradication of occult micrometastatic disease in the adjuvant setting. The 2000 Early Breast Cancer Trialists' Collaborative Group overview of polychemotherapy in breast cancer has demonstrated that anthracycline-based regimens are superior to non-anthracycline-based therapies in terms of disease-free survival and overall survival. The taxanes paclitaxel and docetaxel were well established in metastatic breast cancer and lack cross-resistance with anthracyclines and were therefore quickly deemed worthwhile for evaluation in the adjuvant setting. A large meta-analysis showed that the addition of a taxane to an anthracycline-based regimen improves outcomes in high-risk patients regardless of age, menopausal status, number of nodes involved, hormone receptor status, and type of taxane. There are several effective anthracycline/taxane combinations traditionally studied in patients with high-risk disease. In this overview, we will review some of the key trials that have advanced the standard of care in the adjuvant setting with regard to various chemotherapy combinations. |
| | |
Authors:
|
Devika Gajria; Andrew Seidman; Chau Dang |
Related Documents
:
|
19394894 - Lapatinib monotherapy in patients with her2-overexpressing relapsed or refractory infla... 20926904 - Mitomycin c in patients with gynecological malignancies. 10340904 - Incremental costs of enrolling cancer patients in clinical trials: a population-based s... 20735304 - Lapatinib and breast cancer: current indications and outlook for the future. 18219094 - Matriptase and survivin expression associated with tumor progression and malignant pote... 6279374 - Alveolar trapping in pulmonary carcinomas. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical breast cancer Volume: 10 Suppl 2 ISSN: 1938-0666 ISO Abbreviation: Clin. Breast Cancer Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-31 Completed Date: 2010-12-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100898731 Medline TA: Clin Breast Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: S41-9 Citation Subset: IM |
Affiliation:
|
Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Breast Neoplasms / drug therapy* Chemotherapy, Adjuvant Female Humans Taxoids / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Taxoids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Next Document: Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes...